Skip to main navigation Skip to search Skip to main content

MK2140-011:A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus PolatuzumabVedotin plus R-CHP in Treatment-naïve Participants with GCB Subtype of Diffus

Project: Research

Project Details

StatusActive
Effective start/end date06/12/25 → 12/1/34

Funding

  • Merck Sharp and Dohme Limited Liability Corporation: $25,265.00